TAS2940 for Advanced Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests TAS2940, a new drug for patients with advanced cancers who have no other treatment options. TAS2940 works by blocking proteins that help cancer cells grow. It is effective against certain types of tumors.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What safety data exists for TAS2940 (also known as TAS-102 or TAS-115) in humans?
TAS-102, used for metastatic colorectal cancer, commonly causes bone marrow suppression leading to neutropenia (low white blood cell count), which is a significant side effect. TAS-115, tested in patients with solid tumors and osteosarcoma, was generally well tolerated but also caused neutropenia and other blood-related side effects in some patients. Both treatments have shown manageable toxicities in clinical studies.12345
How does the drug TAS2940 differ from other treatments for advanced cancer?
TAS2940 is unique because it is based on TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), which can selectively induce cell death in cancer cells without affecting normal cells. This drug may overcome resistance seen in other treatments by using highly active TRAIL-receptor agonists and combining with agents that sensitize cancer cells to TRAIL.678910
What data supports the effectiveness of the drug TAS2940 for advanced cancer?
Are You a Good Fit for This Trial?
This trial is for people with advanced solid tumors like breast cancer, lung cancer, or glioblastoma who have no remaining standard treatment options. Participants must have a certain type of tumor change (EGFR/HER2), measurable disease, good organ function and be in fair physical shape (ECOG PS 0-1). Those with unstable brain metastases, serious heart issues or unresolved effects from past cancer treatments cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Assess the safety and determine the maximum tolerated dose, the recommended phase 2 dose, and the recommended dosing regimen of TAS2940 administered orally
Dose Expansion
Assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- TAS2940
Find a Clinic Near You
Who Is Running the Clinical Trial?
Taiho Oncology, Inc.
Lead Sponsor
Tim Whitten
Taiho Oncology, Inc.
Chief Executive Officer since 2018
MBA and Pharmacy degree
Harold Keer
Taiho Oncology, Inc.
Chief Medical Officer
MD, PhD